Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study

Abstract Objective To estimate the infection fatality risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), based on deaths with confirmed coronavirus disease 2019 (covid-19) and excess deaths from all causes. Design Nationwide seroepidemiological study. Setting First wave of covid-19 pandemic in Spain. Participants Community dwelling individuals of all ages. Main outcome measures The main outcome measure was overall, and age and sex specific, infection fatality risk for SARS-CoV-2 (the number of covid-19 deaths and excess deaths divided by the estimated number of SARS-CoV-2 infections) in the community dwelling Spanish population. Deaths with laboratory confirmed covid-19 were obtained from the National Epidemiological Surveillance Network (RENAVE) and excess all cause deaths from the Monitoring Mortality System (MoMo), up to 15 July 2020. SARS-CoV-2 infections in Spain were derived from the estimated seroprevalence by a chemiluminescent microparticle immunoassay for IgG antibodies in 61 098 participants in the ENE-COVID nationwide seroepidemiological survey between 27 April and 22 June 2020. Results The overall infection fatality risk was 0.8% (19 228 of 2.3 million infected individuals, 95% confidence interval 0.8% to 0.9%) for confirmed covid-19 deaths and 1.1% (24 778 of 2.3 million infected individuals, 1.0% to 1.2%) for excess deaths. The infection fatality risk was 1.1% (95% confidence interval 1.0% to 1.2%) to 1.4% (1.3% to 1.5%) in men and 0.6% (0.5% to 0.6%) to 0.8% (0.7% to 0.8%) in women. The infection fatality risk increased sharply after age 50, ranging from 11.6% (8.1% to 16.5%) to 16.4% (11.4% to 23.2%) in men aged 80 or more and from 4.6% (3.4% to 6.3%) to 6.5% (4.7% to 8.8%) in women aged 80 or more. Conclusion The increase in SARS-CoV-2 infection fatality risk after age 50 appeared to be more noticeable in men than in women. Based on the results of this study, fatality from covid-19 was greater than that reported for other common respiratory diseases, such as seasonal influenza.

[1]  J. Arribas,et al.  Impact of COVID-19 on Madrid hospital system. , 2021, Enfermedades infecciosas y microbiologia clinica.

[2]  B. Faivre,et al.  Explaining among-country variation in COVID-19 case fatality rate , 2020, Scientific Reports.

[3]  M. Dake,et al.  Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity , 2020, Immunity.

[4]  M. Battaglini,et al.  Magnitude, demographics and dynamics of the effect of the first wave of the COVID-19 pandemic on all-cause mortality in 21 industrialized countries , 2020, Nature Medicine.

[5]  G. Meyerowitz-Katz,et al.  A systematic review and meta-analysis of published research data on COVID-19 infection fatality rates , 2020, International Journal of Infectious Diseases.

[6]  S. Farhadian,et al.  Sex differences in immune responses that underlie COVID-19 disease outcomes , 2020, Nature.

[7]  Sasikanth Manne,et al.  Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications , 2020, Science.

[8]  C. Tebé,et al.  The natural history of symptomatic COVID-19 in Catalonia, Spain: a multi-state model including 109,367 outpatient diagnoses, 18,019 hospitalisations, and 5,585 COVID-19 deaths among 5,627,520 people , 2020, medRxiv.

[9]  M. Hernán,et al.  Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study , 2020, The Lancet.

[10]  P. Escribano,et al.  Outbreak of COVID-19 in a nursing home in Madrid , 2020, Journal of Infection.

[11]  X. Tang,et al.  Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections , 2020, Nature Medicine.

[12]  S. Lauer,et al.  Serology-informed estimates of SARS-COV-2 infection fatality risk in Geneva, Switzerland , 2020, medRxiv.

[13]  J. López-Sendón,et al.  Influence of age and gender on arrival of patients with ST-segment elevation acute myocardial infarction to tertiary centers during COVID-19 pandemic. Experience of Madrid, Spain, STEMI network (Codigo Infarto Madrid) , 2020, The American Journal of Emergency Medicine.

[14]  C. Suetens,et al.  High impact of COVID-19 in long-term care facilities, suggestion for monitoring in the EU/EEA, May 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[15]  J. Ioannidis,et al.  The infection fatality rate of COVID-19 inferred from seroprevalence data , 2020, medRxiv.

[16]  C. del Rio,et al.  Assessment of Deaths From COVID-19 and From Seasonal Influenza. , 2020, JAMA internal medicine.

[17]  O. Rodriguez-Leor,et al.  Impact of the COVID-19 pandemic on interventional cardiology activity in Spain , 2020, REC: interventional cardiology (English Edition).

[18]  M. Tay,et al.  The trinity of COVID-19: immunity, inflammation and intervention , 2020, Nature Reviews Immunology.

[19]  A. G. Rada,et al.  Covid-19: the precarious position of Spain’s nursing homes , 2020, BMJ.

[20]  U. Seljak,et al.  Total COVID-19 Mortality in Italy: Excess Mortality and Age Dependence through Time-Series Analysis , 2020, medRxiv.

[21]  F. Turkheimer,et al.  COVID-19: Recovering estimates of the infected fatality rate during an ongoing pandemic through partial data , 2020, medRxiv.

[22]  T. Rea,et al.  Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington , 2020, The New England journal of medicine.

[23]  C Jessica E Metcalf,et al.  Use of serological surveys to generate key insights into the changing global landscape of infectious disease , 2016, The Lancet.

[24]  Nigel Shadbolt,et al.  A Linked Data representation of the Nomenclature of Territorial Units for Statistics , 2010, LDSI@FIA.

[25]  J. Nikolich-Žugich The twilight of immunity: emerging concepts in aging of the immune system , 2017, Nature Immunology.

[26]  D. Gómez-Barroso,et al.  [Excess mortality associated with influenza in Spain in winter 2012]. , 2015, Gaceta sanitaria.